$VIRX
Viracta Therapeutics, Inc.

2014 Q4 Form 10-K Financial Statement

#000156459015001589 Filed on March 12, 2015

View on sec.gov

Income Statement

Concept 2014 Q4 2013 Q4 2013 Q1
Revenue $896.0K $1.989M $1.989M
YoY Change -54.95% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.080M $2.700M $2.440M
YoY Change 125.19% 9.31% 11.42%
% of Gross Profit
Research & Development $5.970M $6.880M $7.377M
YoY Change -13.23% -9.35% 10.93%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $7.000K
YoY Change -100.0% -30.0%
% of Gross Profit
Operating Expenses $12.05M $9.580M $9.821M
YoY Change 25.78% -4.77% 11.1%
Operating Profit -$7.832M
YoY Change
Interest Expense -$310.0K -$620.0K $831.0K
YoY Change -50.0% -26.19% -359.69%
% of Operating Profit
Other Income/Expense, Net $10.14M $1.040M -$2.961M
YoY Change 875.0% -78.6% -37.92%
Pretax Income -$1.320M -$7.180M -$11.62M
YoY Change -81.62% 77.28% -16.52%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.320M -$7.180M -$11.62M
YoY Change -81.62% 77.28% -16.49%
Net Earnings / Revenue -147.32% -360.99% -584.41%
Basic Earnings Per Share -$0.02 -$0.13 -$0.23
Diluted Earnings Per Share -$0.02 -$0.15 -$0.23
COMMON SHARES
Basic Shares Outstanding 63.04M 54.06M shares 51.59M
Diluted Shares Outstanding 63.04M 55.57M shares 51.59M

Balance Sheet

Concept 2014 Q4 2013 Q4 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.00M $39.30M $61.00M
YoY Change 9.41% -44.8% 74.79%
Cash & Equivalents $22.19M $15.12M $12.56M
Short-Term Investments $20.80M $24.20M $48.50M
Other Short-Term Assets $1.200M $1.200M $1.200M
YoY Change 0.0% -29.41% -36.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.20M $40.49M $62.20M
YoY Change 9.17% -44.48% 69.48%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $23.00K $0.00
YoY Change 82.61% -46.51% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $10.00K $0.00
YoY Change -100.0% -76.19% -100.0%
Total Long-Term Assets $42.00K $33.00K $100.0K
YoY Change 27.27% -61.18% -50.0%
TOTAL ASSETS
Total Short-Term Assets $44.20M $40.49M $62.20M
Total Long-Term Assets $42.00K $33.00K $100.0K
Total Assets $44.25M $40.53M $62.30M
YoY Change 9.18% -44.5% 68.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.177M $953.0K $1.500M
YoY Change 233.37% 1121.79% 66.67%
Accrued Expenses $8.500M $8.100M $7.300M
YoY Change 4.94% -10.0% 55.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.300M $9.000M $8.200M
YoY Change 3.33% 36.36% 8100.0%
Total Short-Term Liabilities $27.88M $33.97M $35.90M
YoY Change -17.93% 7.03% 182.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $9.000M $15.60M
YoY Change -100.0% -49.15% 64.21%
Other Long-Term Liabilities $2.600M $3.700M $9.700M
YoY Change -29.73% -68.38%
Total Long-Term Liabilities $2.600M $12.70M $25.30M
YoY Change -79.53% -56.8% 166.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.88M $33.97M $35.90M
Total Long-Term Liabilities $2.600M $12.70M $25.30M
Total Liabilities $30.40M $46.70M $61.20M
YoY Change -34.9% -23.57% 175.68%
SHAREHOLDERS EQUITY
Retained Earnings -$522.7M -$479.7M
YoY Change 8.96% 7.77%
Common Stock $536.5M $473.5M
YoY Change 13.3% 3.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.80M -$6.184M $1.100M
YoY Change
Total Liabilities & Shareholders Equity $44.25M $40.53M $62.30M
YoY Change 9.18% -44.5% 68.83%

Cashflow Statement

Concept 2014 Q4 2013 Q4 2013 Q1
OPERATING ACTIVITIES
Net Income -$1.320M -$7.180M -$11.62M
YoY Change -81.62% 77.28% -16.49%
Depreciation, Depletion And Amortization $10.00K $0.00 $7.000K
YoY Change -100.0% -30.0%
Cash From Operating Activities -$9.010M -$9.700M -$9.484M
YoY Change -7.11% 4.75% 1.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.120M -$450.0K $7.750M
YoY Change -793.33% -97.88% 47.9%
Cash From Investing Activities $3.120M -$450.0K $7.752M
YoY Change -793.33% -97.88% 47.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.270M 3.540M -653.0K
YoY Change 105.37% -5.85% -2276.67%
NET CHANGE
Cash From Operating Activities -9.010M -9.700M -9.484M
Cash From Investing Activities 3.120M -450.0K 7.752M
Cash From Financing Activities 7.270M 3.540M -653.0K
Net Change In Cash 1.380M -6.610M -2.385M
YoY Change -120.88% -75.23% -40.82%
FREE CASH FLOW
Cash From Operating Activities -$9.010M -$9.700M -$9.484M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$9.010M -$9.700M
YoY Change -7.11% 4.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67739771
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3087000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1645000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3418000
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24172000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1223000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1199000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522697000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44204000
CY2013Q4 snss Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
10000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
263889528
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22186000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20795000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
40492000
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9257000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29185000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54344000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54344000
CY2013 snss License And Other Revenue
LicenseAndOtherRevenue
7956000
CY2012 snss License And Other Revenue
LicenseAndOtherRevenue
3754000
CY2013 us-gaap Revenues
Revenues
7956000
CY2012 us-gaap Revenues
Revenues
3754000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10838000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9175000
CY2013 us-gaap Operating Expenses
OperatingExpenses
39729000
CY2012 us-gaap Operating Expenses
OperatingExpenses
38360000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-31773000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-34606000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-6184000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27881000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9018000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-479695000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40525000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28891000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11957000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-34598000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7490000
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3543000
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7931000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33972000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2563000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3712000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9025000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44246000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66102000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66102000
CY2014 snss License And Other Revenue
LicenseAndOtherRevenue
5734000
CY2014 us-gaap Revenues
Revenues
5734000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27665000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23112000
CY2014 us-gaap Operating Expenses
OperatingExpenses
50777000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-45043000
CY2014 us-gaap Interest Expense
InterestExpense
1719000
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52249000
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61510000
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48146000
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46894000
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60057000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
13802000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2014Q4 us-gaap Assets
Assets
44246000
CY2013Q4 us-gaap Assets
Assets
40525000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3177000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
953000
CY2014Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
3112000
CY2013Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
4750000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2287000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1719000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7956000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
536499000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473509000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2013 us-gaap Interest Expense
InterestExpense
2917000
CY2012 us-gaap Interest Expense
InterestExpense
1855000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-43951000
CY2012 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
19000
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52249000
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2012 snss Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3130000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
330000
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
621000
CY2012 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000
CY2014 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
3892000
CY2013 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
96000
CY2012 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-7509000
CY2013 snss Exchange Gain Loss On Marketable Securities
ExchangeGainLossOnMarketableSecurities
142000
CY2012 snss Exchange Gain Loss On Marketable Securities
ExchangeGainLossOnMarketableSecurities
82000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3760000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
28020000
CY2012 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
17620000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
172000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3893000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2402000
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
322000
CY2013 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
11986000
CY2013 snss Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
88000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
309000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3581000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
304000
CY2014 snss Adjustments To Additional Paid In Capital Common Stock And Warrant Issued
AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantIssued
40024000
CY2014 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
14292000
CY2014 snss Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
949000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1226000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5882000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
337000
CY2012 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
18124000
CY2013 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
12357000
CY2014 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
14734000
CY2012 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
504000
CY2013 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
371000
CY2014 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
442000
CY2014 snss Issuance Of Common Stock And Warrants In Underwritten Offering
IssuanceOfCommonStockAndWarrantsInUnderwrittenOffering
43013000
CY2014 snss Issuance Of Common Stock And Warrants In Underwritten Offering Issuance Costs
IssuanceOfCommonStockAndWarrantsInUnderwrittenOfferingIssuanceCosts
2989000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6219000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3885000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2724000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
367000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
11000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
43000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-489000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
98000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2224000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
875000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-580000
CY2014 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1638000
CY2013 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-699000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14940000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9311000
CY2014 us-gaap Interest Paid
InterestPaid
1221000
CY2013 us-gaap Interest Paid
InterestPaid
2006000
CY2012 us-gaap Interest Paid
InterestPaid
1165000
CY2014 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
496000
CY2013 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
43000
CY2013 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
11986000
CY2012 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
17620000
CY2012 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3122000
CY2014 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
1961000
CY2013 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
584000
CY2012 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
1918000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46921000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5388000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37642000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7065000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
181000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5629000
CY2012 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
3079000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
568000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
254000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
191000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1674000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-76000
CY2012 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
522000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5687000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7956000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
19624000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-43181000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37423000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10642000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42463000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26894000
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67608000
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45836000
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59110000
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46226000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3325000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
32216000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-21371000
CY2012 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
14982000
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
9356000
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7182000
CY2014 snss Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
40024000
CY2014 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
14292000
CY2012 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
1715000
CY2012 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
770000
CY2014 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
9337000
CY2012 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
402000
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p></div>
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2014Q4 snss Other Accruals Current
OtherAccrualsCurrent
76000
CY2013Q4 snss Other Accruals Current
OtherAccrualsCurrent
133000
CY2014Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
900000
CY2014Q2 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
2000000
CY2014Q4 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
CY2014 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2014 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
43000000
CY2014 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2014 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2014 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2014Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2013Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
2600000
CY2010Q4 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingGross
15500000
CY2014 snss Measurement Dates Of Fair Market Value For Employee Stock Purchase Plan Purchases
MeasurementDatesOfFairMarketValueForEmployeeStockPurchasePlanPurchases
At the beginning of a 12-month offering period or at the end of one of the two related six-month purchase periods.
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3892000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1453000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19562000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17589000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16647000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30334000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30327000
CY2014Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
9532000
CY2014Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
20802000
CY2014Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9532000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30758000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30755000
CY2013Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
6583000
CY2013Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
24175000
CY2013Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
3000
CY2013Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
6000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6583000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
7000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
11782000
CY2014 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2012 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q4 snss Common Stock Fair Value
CommonStockFairValue
2.55
CY2013Q4 snss Common Stock Fair Value
CommonStockFairValue
4.74
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9M18D
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y9M18D
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.449
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.608
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.002
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.003
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2014Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
1.21
CY2013Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
2.56
CY2014Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
2920000
CY2013Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
3099000
CY2014Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
2656000
CY2013Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
1249000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
355000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingGross
43000000
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Net
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingNet
40000000
CY2014Q4 snss Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2011Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2014 snss Number Of Tranches For Maximum Borrowing
NumberOfTranchesForMaximumBorrowing
2
CY2014 snss Line Of Credit Facility Number Of Installments
LineOfCreditFacilityNumberOfInstallments
32
CY2014 snss Line Of Credit Facility Final Payment
LineOfCreditFacilityFinalPayment
937500
CY2014Q4 us-gaap Notes Payable
NotesPayable
9257000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
247000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
247000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2014 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
99049000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1104000
CY2014Q4 snss Share Based Compensation Arrangement Outstanding Securities
ShareBasedCompensationArrangementOutstandingSecurities
22482000
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23586000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3400000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2014 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7611000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3840000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
565000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
302000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10584000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10584000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5701000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.61
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.54
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.17
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.13
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.93
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.93
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.86
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M17D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M17D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M26D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3885000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3885000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2075000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2700000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2014 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12200000
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-32696000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29963000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-43951000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10306000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4635000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43002000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34598000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43951000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14620000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11763000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14943000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-14104000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-12457000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-5351000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
3504000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1499000
CY2014 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
1934000
CY2013 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
2706000
CY2012 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
-6672000
CY2014 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
-1313000
CY2013 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
-16000
CY2012 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
2570000
CY2014 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
259000
CY2013 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
529000
CY2012 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
350000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
138066000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
123490000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12964000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12064000
CY2014Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
5199000
CY2013Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
5119000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2394000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4668000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4358000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3212000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
129000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
133000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
481000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
341000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
163591000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
149027000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
163591000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
149027000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14600000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12600000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13700000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 snss Indemnification Liabilities Incurred
IndemnificationLiabilitiesIncurred
0
CY2014Q1 us-gaap Revenues
Revenues
1995000
CY2014Q2 us-gaap Revenues
Revenues
1989000
CY2014Q3 us-gaap Revenues
Revenues
854000
CY2014Q4 us-gaap Revenues
Revenues
896000
CY2013Q1 us-gaap Revenues
Revenues
1989000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14573000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11781000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15325000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1323000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11624000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14573000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12114000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15325000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1323000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11624000
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56313000
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60246000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60549000
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63041000
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51587000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56313000
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61895000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60549000
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63041000
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51587000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23

Files In Submission

Name View Source Status
0001564590-15-001589-index-headers.html Edgar Link pending
0001564590-15-001589-index.html Edgar Link pending
0001564590-15-001589.txt Edgar Link pending
0001564590-15-001589-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503121959121924998.jpg Edgar Link pending
g201503121959191764999.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10k_20141231.htm Edgar Link pending
snss-20141231.xml Edgar Link completed
snss-20141231.xsd Edgar Link pending
snss-20141231_cal.xml Edgar Link unprocessable
snss-20141231_def.xml Edgar Link unprocessable
snss-20141231_lab.xml Edgar Link unprocessable
snss-20141231_pre.xml Edgar Link unprocessable
snss-ex1044_20141231650.htm Edgar Link pending
snss-ex231_20141231250.htm Edgar Link pending
snss-ex311_20141231251.htm Edgar Link pending
snss-ex312_20141231252.htm Edgar Link pending
snss-ex321_20141231253.htm Edgar Link pending